(NewsDirect)
Cardiol Therapeutics CEO David Elsley shared news the company hashit a major milestone in that the first patient has been enrolled in aPhase II open-label pilot study of CardiolRx in patients withrecurrent pericarditis. Elsley told Proactive the study is designed toevaluate improvement in objective measures of disease and assess thefeasibility of weaning concomitant background therapy includingcorticosteroids, while taking CardiolRx. The study is expected toenroll 25 patents.
ProactiveCanada Financial News
ContactDetails
Proactive Canada
ProactiveCanada
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.